Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring <i>EGFR</i> mutation: an observational clinical study.

Ther Adv Med Oncol · 2023 · PMC10262622 · PMID 37323187

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Regarding first-line afatinib, the LUX-Lung 7 phase IIb study showed a trend toward better OS in patients treated with afatinib ( n = 160) compared with gefitinib ( n = 159). 3 Furthermore, the retrospective Gio-Tag study, which included real-world clinical patients treated with first-line afatinib followed by second-line osimertinib, found that the median duration of s

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.